论文部分内容阅读
目的探讨肾康联合前列地尔治疗慢性肾功能衰竭(Chronic renal failure,CRF)的临床疗效。方法选择CRF患者37例,随机分为对照组和治疗组,对照组给予肾康和常规对症治疗,治疗组在上述基础上增加前列地尔,观察患者治疗前和治疗后14d后,检测24h尿蛋白(Pro)、血清肌酐(Scr)、血内生肌酐清除率(Ccr)和尿素氮(BUN)。结果与治疗前比较,对照组和治疗组治疗后Scr和BUN显著降低,Ccr显著升高(P<0.05或P<0.01)。与对照组治疗后比较,治疗组治疗后24hPro、Scr和BUN较低(P<0.05),Ccr较高(P<0.05)。两组患者临床有效率分别为77.77%和89.47%,且在临床疗效方面具有统计学差异(P<0.05)。结论肾康联合前列地尔可显著改善CRF患者肾功能。
Objective To investigate the clinical efficacy of Shenkang combined with alprostadil in the treatment of chronic renal failure (CRF). Methods Thirty-seven patients with CRF were randomly divided into control group and treatment group. The control group was given Shenkang and conventional symptomatic treatment. The treatment group was given alprostadil on the basis of the above. Before and after treatment, the patients were observed for 24h urine Pro, Scr, Ccr and BUN. Results Compared with those before treatment, the Scr and BUN in the control group and the treatment group were significantly decreased and Ccr was significantly increased (P <0.05 or P <0.01). Compared with the control group, 24hPro, Scr and BUN in the treatment group were lower (P <0.05) and Ccr were higher (P <0.05). The clinical efficacies of the two groups were 77.77% and 89.47%, respectively, and there was a statistically significant difference in clinical efficacy (P <0.05). Conclusion Shenkang combined with alprostadil can significantly improve renal function in patients with CRF.